Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients.

Lin SY, Orozco JIJ, Hoon DSB.

Adv Exp Med Biol. 2018;1100:83-95. doi: 10.1007/978-3-319-97746-1_5.

PMID:
30411261
2.

Epigenetic profiling for the molecular classification of metastatic brain tumors.

Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, Salomon MP, Barkhoudarian G, Jalas JR, Wilmott JS, Hothi P, Wang X, Takasumi Y, Buckland ME, Thompson JF, Long GV, Cobbs CS, Shmulevich I, Kelly DF, Scolyer RA, Hoon DSB, Marzese DM.

Nat Commun. 2018 Nov 6;9(1):4627. doi: 10.1038/s41467-018-06715-y.

3.

Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features.

Salomon MP, Orozco JIJ, Wilmott JS, Hothi P, Manughian-Peter AO, Cobbs CS, Scolyer RA, Hoon DSB, Marzese DM.

Sci Data. 2018 Nov 6;5:180245. doi: 10.1038/sdata.2018.245.

4.

Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.

Iida Y, Salomon MP, Hata K, Tran K, Ohe S, Griffiths CF, Hsu SC, Nelson N, Hoon DSB.

BMC Cancer. 2018 Oct 30;18(1):1054. doi: 10.1186/s12885-018-4977-2.

5.

Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.

Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W, Xu M, Zhong P, Yu S, Chen D, Ding X, Zhang Y, Zheng X, Yang J, Qian J, Deng Y, Hoon DSB, Hu J, Chu Y, Zhou L.

Cancer Immunol Immunother. 2018 Nov;67(11):1777-1788. doi: 10.1007/s00262-018-2232-y. Epub 2018 Aug 22.

PMID:
30159779
6.

The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes.

Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, Matsuba C, Takasumi Y, Ballesteros-Merino C, Fox BA, Barkhoudarian G, Kelly DF, Hoon DSB.

Clin Cancer Res. 2018 Sep 1;24(17):4126-4136. doi: 10.1158/1078-0432.CCR-17-2206. Epub 2018 Jul 3.

PMID:
30084836
7.

The metastatic microenvironment: Melanoma-microglia cross-talk promotes the malignant phenotype of melanoma cells.

Izraely S, Ben-Menachem S, Sagi-Assif O, Telerman A, Zubrilov I, Ashkenazi O, Meshel T, Maman S, Orozco JIJ, Salomon MP, Marzese DM, Pasmanik-Chor M, Pikarski E, Ehrlich M, Hoon DSB, Witz IP.

Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31745. [Epub ahead of print]

PMID:
29992556
8.

Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.

Graff-Baker AN, Orozco JIJ, Marzese DM, Salomon MP, Hoon DSB, Goldfarb M.

Ann Surg Oncol. 2018 Oct;25(10):3082-3087. doi: 10.1245/s10434-018-6582-7. Epub 2018 Jun 28.

PMID:
29956094
9.

KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.

Wang W, Lim KG, Feng M, Bao Y, Lee PL, Cai Y, Chen Y, Zhang H, Marzese D, Hoon DSB, Yu Q.

Mol Cancer Ther. 2018 Sep;17(9):1973-1983. doi: 10.1158/1535-7163.MCT-17-0802. Epub 2018 Jun 20.

PMID:
29925528
10.

Alternative splicing and cancer metastasis: prognostic and therapeutic applications.

Marzese DM, Manughian-Peter AO, Orozco JIJ, Hoon DSB.

Clin Exp Metastasis. 2018 Aug;35(5-6):393-402. doi: 10.1007/s10585-018-9905-y. Epub 2018 May 29.

PMID:
29845349
11.

miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.

Li W, Yi J, Zheng X, Liu S, Fu W, Ren L, Li L, Hoon DSB, Wang J, Du G.

Clin Epigenetics. 2018 May 16;10:64. doi: 10.1186/s13148-018-0495-y. eCollection 2018.

12.

Distinct histone modifications denote early stress-induced drug tolerance in cancer.

Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H.

Oncotarget. 2017 Dec 24;9(9):8206-8222. doi: 10.18632/oncotarget.23654. eCollection 2018 Feb 2.

13.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

14.

ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis.

Izraely S, Ben-Menachem S, Sagi-Assif O, Meshel T, Marzese DM, Ohe S, Zubrilov I, Pasmanik-Chor M, Hoon DSB, Witz IP.

Oncotarget. 2017 Jul 5;8(44):75778-75796. doi: 10.18632/oncotarget.19018. eCollection 2017 Sep 29.

15.

Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.

Goh JY, Feng M, Wang W, Oguz G, Yatim SMJM, Lee PL, Bao Y, Lim TH, Wang P, Tam WL, Kodahl AR, Lyng MB, Sarma S, Lin SY, Lezhava A, Yap YS, Lim AST, Hoon DSB, Ditzel HJ, Lee SC, Tan EY, Yu Q.

Nat Med. 2017 Nov;23(11):1319-1330. doi: 10.1038/nm.4405. Epub 2017 Sep 25.

PMID:
28967919
16.

P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.

Wang J, Hirose H, Du G, Chong K, Kiyohara E, Witz IP, Hoon DSB.

Cancer Lett. 2017 Oct 28;407:66-75. doi: 10.1016/j.canlet.2017.08.001. Epub 2017 Aug 10.

PMID:
28803992
17.

Hypomethylation of CNTFRα is associated with proliferation and poor prognosis in lower grade gliomas.

Fan K, Wang X, Zhang J, Ramos RI, Zhang H, Li C, Ye D, Kang J, Marzese DM, Hoon DSB, Hua W.

Sci Rep. 2017 Aug 1;7(1):7079. doi: 10.1038/s41598-017-07124-9.

18.

NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1α and p27Kip1 expression in malignant melanoma and other human tumors.

Antony S, Jiang G, Wu Y, Meitzler JL, Makhlouf HR, Haines DC, Butcher D, Hoon DS, Ji J, Zhang Y, Juhasz A, Lu J, Liu H, Dahan I, Konate M, Roy KK, Doroshow JH.

Mol Carcinog. 2017 Dec;56(12):2643-2662. doi: 10.1002/mc.22708. Epub 2017 Aug 30.

19.

Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.

Lin SY, Linehan JA, Wilson TG, Hoon DSB.

Eur Urol Focus. 2017 Apr;3(2-3):265-272. doi: 10.1016/j.euf.2017.03.009. Epub 2017 Mar 31. Review.

PMID:
28753876
20.

The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas.

Ruiz R, Jahid S, Harris M, Marzese DM, Espitia F, Vasudeva P, Chen CF, de Feraudy S, Wu J, Gillen DL, Krasieva TB, Tromberg BJ, Pavan WJ, Hoon DS, Ganesan AK.

PLoS Genet. 2017 Jul 28;13(7):e1006913. doi: 10.1371/journal.pgen.1006913. eCollection 2017 Jul.

21.

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM.

N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.

22.

MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.

Bustos MA, Ono S, Marzese DM, Oyama T, Iida Y, Cheung G, Nelson N, Hsu SC, Yu Q, Hoon DSB.

J Invest Dermatol. 2017 Sep;137(9):1955-1964. doi: 10.1016/j.jid.2017.03.039. Epub 2017 May 16.

23.

CCR4 is a determinant of melanoma brain metastasis.

Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S, Bayry J, Marzese DM, Ohe S, Hoon DSB, Erez N, Witz IP.

Oncotarget. 2017 May 9;8(19):31079-31091. doi: 10.18632/oncotarget.16076.

24.

Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.

Iida Y, Ciechanover A, Marzese DM, Hata K, Bustos M, Ono S, Wang J, Salomon MP, Tran K, Lam S, Hsu S, Nelson N, Kravtsova-Ivantsiv Y, Mills GB, Davies MA, Hoon DSB.

Clin Cancer Res. 2017 Aug 15;23(16):4831-4842. doi: 10.1158/1078-0432.CCR-17-0146. Epub 2017 Apr 7.

25.

ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.

Chen CF, Ruiz-Vega R, Vasudeva P, Espitia F, Krasieva TB, de Feraudy S, Tromberg BJ, Huang S, Garner CP, Wu J, Hoon DS, Ganesan AK.

Cell Rep. 2017 Mar 7;18(10):2331-2342. doi: 10.1016/j.celrep.2017.02.040.

26.

Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.

Bustos MA, Salomon MP, Nelson N, Hsu SC, DiNome ML, Hoon DS, Marzese DM.

Genom Data. 2017 Feb 14;12:14-16. doi: 10.1016/j.gdata.2017.01.002. eCollection 2017 Jun.

27.

The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.

Jones MS, Jones PC, Stern SL, Elashoff D, Hoon DSB, Thompson J, Mozzillo N, Nieweg OE, Noyes D, Hoekstra HJ, Zager JS, Roses DF, Testori A, Coventry BJ, Smithers MB, Andtbacka R, Agnese D, Schultz E, Hsueh EC, Kelley M, Schneebaum S, Jacobs L, Bowles T, Kashani-Sabet M, Johnson D, Faries MB.

Ann Surg Oncol. 2017 Aug;24(8):2089-2094. doi: 10.1245/s10434-017-5775-9. Epub 2017 Feb 21.

28.

LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.

Nagai Y, Sunami E, Yamamoto Y, Hata K, Okada S, Murono K, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Ishihara S, Hoon DS, Watanabe T.

Oncotarget. 2017 Feb 14;8(7):11906-11916. doi: 10.18632/oncotarget.14439.

30.

Preface: The Living Legacy of Donald L. Morton.

Hoon DS.

Crit Rev Oncog. 2016;21(1-2):v-vi0. doi: 10.1615/CritRevOncog.2016016917. No abstract available.

PMID:
27481011
31.

Liquid Biopsies for Assessing Metastatic Melanoma Progression.

Huynh K, Hoon DS.

Crit Rev Oncog. 2016;21(1-2):141-54. doi: 10.1615/CritRevOncog.2016016075. Review.

32.

Donald L. Morton, MD.... A Legendary Surgical Oncologist and Consummate Investigator.

Balch CM, Hoon DS.

Crit Rev Oncog. 2016;21(1-2):3-5. doi: 10.1615/CritRevOncog.2016016918. No abstract available.

PMID:
27480997
33.

Donald L. Morton, MD 1934-2014.

Hoon DS.

Crit Rev Oncog. 2016;21(1-2):1-2. doi: 10.1615/CritRevOncog.2016017122. No abstract available.

PMID:
27480996
34.

Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?

Leung F, Kulasingam V, Diamandis EP, Hoon DS, Kinzler K, Pantel K, Alix-Panabières C.

Clin Chem. 2016 Aug;62(8):1054-60. doi: 10.1373/clinchem.2016.260331. Epub 2016 Jun 3. No abstract available.

35.

B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.

Yao Y, Ye H, Qi Z, Mo L, Yue Q, Baral A, Hoon DSB, Vera JC, Heiss JD, Chen CC, Zhang J, Jin K, Wang Y, Zang X, Mao Y, Zhou L.

Clin Cancer Res. 2016 Jun 1;22(11):2778-2790. doi: 10.1158/1078-0432.CCR-15-0858. Epub 2016 Mar 21.

36.

Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.

Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL Jr, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA.

Clin Cancer Res. 2016 Jun 15;22(12):3016-24. doi: 10.1158/1078-0432.CCR-15-2226. Epub 2016 Jan 18.

37.

Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.

Huang SK, Hoon DS.

Mol Oncol. 2016 Mar;10(3):450-63. doi: 10.1016/j.molonc.2015.12.008. Epub 2015 Dec 17. Review.

38.
39.

Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives.

Marzese DM, Witz IP, Kelly DF, Hoon DS.

Epigenomics. 2015;7(8):1303-11. doi: 10.2217/epi.15.77. Epub 2015 Dec 7. Review.

PMID:
26638944
40.

Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Wee ZN, Yatim SM, Kohlabauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q.

Nat Commun. 2015 Nov 20;6:10054. doi: 10.1038/ncomms10054. No abstract available.

PMID:
26585835
41.

Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays.

Ono S, Lam S, Nagahara M, Hoon DS.

J Clin Med. 2015 Oct 23;4(10):1890-907. doi: 10.3390/jcm4101890. Review. Erratum in: J Clin Med. 2016;5(9). pii: E81. doi: 10.3390/jcm5090081.

42.

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q.

Nat Commun. 2015 Oct 27;6:8746. doi: 10.1038/ncomms9746. Erratum in: Nat Commun. 2015;6:10054. Yi, Bao [Corrected to Bao, Yi].

43.

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.

Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, Kermani BG, Eltoukhy H, Talasaz A.

PLoS One. 2015 Oct 16;10(10):e0140712. doi: 10.1371/journal.pone.0140712. eCollection 2015.

44.

RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb.

Wang J, Hua W, Huang SK, Fan K, Takeshima L, Mao Y, Hoon DS.

Oncotarget. 2015 Oct 6;6(30):30165-77. doi: 10.18632/oncotarget.5030.

45.

Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications.

Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, Jones P, Somers EB, O'Shannessy DJ, Hoon DS.

Cancer Microenviron. 2015 Aug;8(2):111-8. doi: 10.1007/s12307-015-0168-8. Epub 2015 Jun 18.

46.

The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching.

Lessard L, Liu M, Marzese DM, Wang H, Chong K, Kawas N, Donovan NC, Kiyohara E, Hsu S, Nelson N, Izraely S, Sagi-Assif O, Witz IP, Ma XJ, Luo Y, Hoon DSB.

J Invest Dermatol. 2015 Oct;135(10):2464-2474. doi: 10.1038/jid.2015.200. Epub 2015 May 27.

47.

Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma.

Sundarasetty BS, Chan L, Darling D, Giunti G, Farzaneh F, Schenck F, Naundorf S, Kuehlcke K, Ruggiero E, Schmidt M, von Kalle C, Rothe M, Hoon DS, Gerasch L, Figueiredo C, Koehl U, Blasczyk R, Gutzmer R, Stripecke R.

Gene Ther. 2015 Sep;22(9):707-20. doi: 10.1038/gt.2015.43. Epub 2015 May 28.

48.

Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer.

Marzese DM, Hoon DS.

Expert Rev Mol Diagn. 2015 May;15(5):647-64. doi: 10.1586/14737159.2015.1027194. Epub 2015 Mar 22. Review.

49.
50.

Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.

Zubrilov I, Sagi-Assif O, Izraely S, Meshel T, Ben-Menahem S, Ginat R, Pasmanik-Chor M, Nahmias C, Couraud PO, Hoon DS, Witz IP.

Cancer Lett. 2015 May 28;361(1):86-96. doi: 10.1016/j.canlet.2015.02.041. Epub 2015 Feb 25.

PMID:
25725450

Supplemental Content

Support Center